Q2 EPS Estimate for Rhythm Pharmaceuticals Cut by Analyst

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Investment analysts at HC Wainwright cut their Q2 2025 earnings per share estimates for Rhythm Pharmaceuticals in a research report issued on Thursday, May 8th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.76) per share for the quarter, down from their previous estimate of ($0.72). HC Wainwright has a “Buy” rating and a $80.00 price objective on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.74) EPS, FY2025 earnings at ($3.01) EPS, Q1 2026 earnings at ($0.66) EPS, Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.28) EPS, Q4 2026 earnings at ($0.19) EPS and FY2026 earnings at ($1.53) EPS.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last announced its quarterly earnings results on Wednesday, May 7th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.12). Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The firm had revenue of $37.72 million for the quarter, compared to analyst estimates of $40.43 million. During the same period in the previous year, the business posted ($2.35) earnings per share. The business’s revenue for the quarter was up 25.9% compared to the same quarter last year.

Several other equities research analysts have also commented on the company. Bank of America upgraded Rhythm Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $63.00 target price on the stock in a research report on Monday, April 7th. Morgan Stanley restated an “overweight” rating and issued a $72.00 price target on shares of Rhythm Pharmaceuticals in a report on Friday, March 7th. Canaccord Genuity Group upped their price objective on shares of Rhythm Pharmaceuticals from $81.00 to $92.00 and gave the company a “buy” rating in a report on Tuesday, April 8th. Needham & Company LLC raised their target price on Rhythm Pharmaceuticals from $66.00 to $72.00 and gave the company a “buy” rating in a research note on Wednesday, May 7th. Finally, Stifel Nicolaus assumed coverage on Rhythm Pharmaceuticals in a report on Wednesday, March 5th. They issued a “buy” rating and a $78.00 price target on the stock. Thirteen equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $75.38.

Rhythm Pharmaceuticals Stock Performance

NASDAQ:RYTM opened at $56.79 on Monday. Rhythm Pharmaceuticals has a fifty-two week low of $35.17 and a fifty-two week high of $68.58. The company has a 50 day simple moving average of $57.07 and a two-hundred day simple moving average of $57.17. The company has a market capitalization of $3.61 billion, a PE ratio of -13.12 and a beta of 2.36.

Institutional Trading of Rhythm Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in RYTM. Algert Global LLC increased its stake in shares of Rhythm Pharmaceuticals by 47.9% during the 1st quarter. Algert Global LLC now owns 61,461 shares of the company’s stock worth $3,256,000 after purchasing an additional 19,910 shares during the last quarter. Aberdeen Group plc raised its stake in shares of Rhythm Pharmaceuticals by 34.3% in the first quarter. Aberdeen Group plc now owns 108,129 shares of the company’s stock valued at $5,728,000 after buying an additional 27,612 shares during the period. Fox Run Management L.L.C. purchased a new position in shares of Rhythm Pharmaceuticals during the 1st quarter valued at $1,016,000. E Fund Management Co. Ltd. purchased a new position in shares of Rhythm Pharmaceuticals during the 1st quarter valued at $286,000. Finally, Russell Investments Group Ltd. increased its holdings in Rhythm Pharmaceuticals by 11,412.3% in the 1st quarter. Russell Investments Group Ltd. now owns 114,778 shares of the company’s stock worth $6,080,000 after acquiring an additional 113,781 shares during the last quarter.

Insider Buying and Selling at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, insider Joseph Shulman sold 1,228 shares of the company’s stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $57.22, for a total value of $70,266.16. Following the completion of the transaction, the insider now owns 8,509 shares in the company, valued at $486,884.98. This represents a 12.61% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Yann Mazabraud sold 75,000 shares of the firm’s stock in a transaction on Friday, March 14th. The shares were sold at an average price of $51.48, for a total value of $3,861,000.00. Following the sale, the executive vice president now directly owns 40,370 shares of the company’s stock, valued at approximately $2,078,247.60. This represents a 65.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 143,639 shares of company stock worth $8,023,381. Insiders own 5.60% of the company’s stock.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.